Anebulo Pharmaceuticals (NASDAQ:ANEB) Releases Earnings Results

Anebulo Pharmaceuticals (NASDAQ:ANEB) announced its quarterly earnings data on Thursday. The company reported ($0.05) earnings per share (EPS) for the quarter, FiscalAI reports.

Anebulo Pharmaceuticals Price Performance

Shares of NASDAQ ANEB traded down $0.04 during trading hours on Friday, hitting $2.33. 11,943 shares of the stock were exchanged, compared to its average volume of 139,128. Anebulo Pharmaceuticals has a one year low of $0.80 and a one year high of $3.42. The company’s 50 day moving average is $2.46 and its 200 day moving average is $2.01. The firm has a market capitalization of $95.73 million, a P/E ratio of -8.96 and a beta of -0.88.

Institutional Investors Weigh In On Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. purchased a new stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned about 0.12% of Anebulo Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 28.40% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on ANEB shares. Maxim Group lowered Anebulo Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Anebulo Pharmaceuticals in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Anebulo Pharmaceuticals has an average rating of “Hold” and an average price target of $5.50.

Anebulo Pharmaceuticals Company Profile

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.